Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on INSP stock, giving a Buy rating yesterday. Anthony ...

Do you suffer from sleep apnea and long for a peaceful night’s sleep and solution to your snoring? Holy Cross Medical Group pulmonologist Ronald Scott, M.D. will speak about Inspire®, an FDA-approved ...

Inspire Medical Systems shares are up today on third-quarter results that came in ahead of the consensus forecast.

Dr. Wise from CAMC not only offers ‘Inspire’ therapy to treat his patients' sleep apnea - he’s also using ‘Inspire’ to treat ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Good afternoon. My name is Dilem, and I’ll be your conference ...

Inspire is increasing its full year 2024 revenue guidance to between $793 million to $798 million, which represents growth of 27% to 28% over full year 2023 revenue of $624.8 million. This compares to ...

Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to ...

“We are very proud of how the team executed in the third quarter, effectively treating patients with Inspire therapy, bringing the total number of patients treated to over 85,000. This ...

Let's start with what is most important and that is the delivery of safe and effective therapy to our patients. And as of this call, we have surpassed 85,000 patients who have received Inspire ...

“Further, a key peer-reviewed study was published demonstrating the long-term safety of Inspire therapy assessing real-world experience since original FDA approval in 2014.” Revenue was $203.2 ...